Healthcare Jul 14, 2021 09:25 AM (GMT+8) · EqualOcean
Recently, Xinwen bio has completed tens of millions of angel rounds of financing, jointly invested by enshe, family office and Yongguan new materials, a listed company. This round of financing will be used for the industrialization of Yimei dahealth transdermal products and the clinical research and development of innovative transdermal drugs in pain management, neurology and other fields. Established in April 2015, Xinwen bio is committed to the research, development, production, sales and cooperative development of new transdermal drugs and health products with innovative and clinical advantages in the fields of pain management, neurology and Yimei health. Zhang Xin, the founder of the company, once served as the technical director of Alza, a pioneer enterprise of modern transdermal drug delivery technology, and the global director of chemical division of Johnson & Johnson company. The founding members of the company have more than 20 years of R & D and management experience in the transdermal drug delivery industry, Its technology and management team has a mature technical reserve of transdermal drug delivery, and has successfully developed and completed the industrialization of a number of innovative transdermal preparations at home and abroad. Xinwen bio has a number of core transdermal drug delivery technologies: core transdermal technology platform with high drug loading and high permeability, its own artificial cuticle screening model, transdermal prescription technology platform, etc. Relying on the above technology platform, Xinwen bio has completed a number of transdermal drug delivery pipeline reserves, most of which are the world's first.